Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Maravai LifeSciences Holdings stock price, quote, forecast and news

MRVI
US56600D1072
A2QHK8

Price

8.81
Today +/-
-0.15
Today %
-1.91 %
P

Maravai LifeSciences Holdings stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Maravai LifeSciences Holdings stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Maravai LifeSciences Holdings stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Maravai LifeSciences Holdings stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Maravai LifeSciences Holdings's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Maravai LifeSciences Holdings Stock Price History

DateMaravai LifeSciences Holdings Price
9/11/20248.81 undefined
9/10/20248.98 undefined
9/9/20248.87 undefined
9/6/20249.05 undefined
9/5/20248.64 undefined
9/4/20248.18 undefined
9/3/20248.73 undefined
8/30/20249.05 undefined
8/29/20249.21 undefined
8/28/20249.16 undefined
8/27/20249.03 undefined
8/26/20248.78 undefined
8/23/20248.91 undefined
8/22/20248.86 undefined
8/21/20248.78 undefined
8/20/20248.99 undefined
8/19/20249.24 undefined
8/16/20249.68 undefined
8/15/20247.97 undefined
8/14/20248.22 undefined

Maravai LifeSciences Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Maravai LifeSciences Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Maravai LifeSciences Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Maravai LifeSciences Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Maravai LifeSciences Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Maravai LifeSciences Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Maravai LifeSciences Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Maravai LifeSciences Holdings’s growth potential.

Maravai LifeSciences Holdings Revenue, EBIT and net profit per share

DateMaravai LifeSciences Holdings RevenueMaravai LifeSciences Holdings EBITMaravai LifeSciences Holdings Net Income
2028e550.38 M undefined126.48 M undefined97.77 M undefined
2027e440.3 M undefined98.94 M undefined56.6 M undefined
2026e347.84 M undefined64.29 M undefined26.9 M undefined
2025e302.81 M undefined38.79 M undefined5.74 M undefined
2024e281.11 M undefined20.52 M undefined-8.31 M undefined
2023288.95 M undefined-25.18 M undefined-119.03 M undefined
2022883 M undefined574.2 M undefined220.2 M undefined
2021799.2 M undefined543.4 M undefined182 M undefined
2020284.1 M undefined100.9 M undefined76.9 M undefined
2019143.1 M undefined24 M undefined-8.5 M undefined
2018123.8 M undefined16.4 M undefined-17.7 M undefined

Maravai LifeSciences Holdings Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e2026e2027e2028e
123143284799883288281302347440550
-16.2698.60181.3410.51-67.38-2.437.4714.9026.8025.00
51.2253.1571.8382.3580.8648.61-----
637620465871414000000
1624100543574-2520386498126
13.0116.7835.2167.9665.01-8.687.1212.5818.4422.2722.91
-17-876182220-119-85265697
--52.94-1,050.00139.4720.88-154.09-93.28-162.50420.00115.3873.21
257.6257.6257.6257.8255.3131.9200000
-----------
Details

Keystats

ⓘ

Revenue and Growth

The Maravai LifeSciences Holdings Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Maravai LifeSciences Holdings is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
201820192020202120222023
           
21.924.7236.2551.3632.1574.96
1618.851.2117.5138.654.61
00008.21.12
14.314.233.351.643.251.4
1.62.810.919.725.817.83
53.860.5331.6740.1847.9699.91
42.694.3101.395.4116.6222.65
000000
000000
218.1197.9177.7117.6216.7220.99
224.3224.3224.3152.8283.7326.03
0.90.8435.9812.5817.517.88
0.490.520.941.181.430.79
0.540.581.271.922.281.49
           
182.8183.92.62.62.62.51
0085.1128.4137.9128.5
-38.2-42.40.9184.6404.8285.74
-0.2-0.10000
000000
144.4141.488.6315.6545.3416.75
3.67.58.28.2610.73
11.116.52929.350.656.58
18.73.187.650.348.114.09
000000
2.52.5665.46.07
35.929.6130.893.8110.187.47
337.4387.7584.8524.6522550.6
15.914.78.6000
2.51.2391.8754.5744.959.49
0.360.40.991.281.270.61
0.390.431.121.371.380.7
0.540.571.21.691.921.11
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Maravai LifeSciences Holdings provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Maravai LifeSciences Holdings's financial health and stability.

Assets

Maravai LifeSciences Holdings's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Maravai LifeSciences Holdings must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Maravai LifeSciences Holdings after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Maravai LifeSciences Holdings's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201820192020202120222023
-16-578469490-138
222425243140
0-1-54642754
-15235-176-4597
125411434-593
252828272044
0052223-2
024152368536126
-3-17-25-14-17-65
-3-176105-267-122
0031120-250-56
000000
55-2196-6-5-5
00301120
-9-453-159-187-61
-64.00-1.00-445.00-154.00-184.00-55.00
000000
-13221131580-57
-3.87126.8353.7518.960.67
000000

Maravai LifeSciences Holdings stock margins

The Maravai LifeSciences Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Maravai LifeSciences Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Maravai LifeSciences Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Maravai LifeSciences Holdings's sales revenue. A higher gross margin percentage indicates that the Maravai LifeSciences Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Maravai LifeSciences Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Maravai LifeSciences Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Maravai LifeSciences Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Maravai LifeSciences Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Maravai LifeSciences Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Maravai LifeSciences Holdings Margin History

Maravai LifeSciences Holdings Gross marginMaravai LifeSciences Holdings Profit marginMaravai LifeSciences Holdings EBIT marginMaravai LifeSciences Holdings Profit margin
2028e48.52 %22.98 %17.76 %
2027e48.52 %22.47 %12.86 %
2026e48.52 %18.48 %7.73 %
2025e48.52 %12.81 %1.9 %
2024e48.52 %7.3 %-2.96 %
202348.52 %-8.72 %-41.19 %
202280.86 %65.03 %24.94 %
202182.42 %67.99 %22.77 %
202071.95 %35.52 %27.07 %
201953.32 %16.77 %-5.94 %
201850.97 %13.25 %-14.3 %

Maravai LifeSciences Holdings Stock Sales Revenue, EBIT, Earnings per Share

The Maravai LifeSciences Holdings earnings per share therefore indicates how much revenue Maravai LifeSciences Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Maravai LifeSciences Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Maravai LifeSciences Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Maravai LifeSciences Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Maravai LifeSciences Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Maravai LifeSciences Holdings Revenue, EBIT and net profit per share

DateMaravai LifeSciences Holdings Sales per ShareMaravai LifeSciences Holdings EBIT per shareMaravai LifeSciences Holdings Earnings per Share
2028e2.18 undefined0 undefined0.39 undefined
2027e1.75 undefined0 undefined0.22 undefined
2026e1.38 undefined0 undefined0.11 undefined
2025e1.2 undefined0 undefined0.02 undefined
2024e1.11 undefined0 undefined-0.03 undefined
20232.19 undefined-0.19 undefined-0.9 undefined
20223.46 undefined2.25 undefined0.86 undefined
20213.1 undefined2.11 undefined0.71 undefined
20201.1 undefined0.39 undefined0.3 undefined
20190.56 undefined0.09 undefined-0.03 undefined
20180.48 undefined0.06 undefined-0.07 undefined

Maravai LifeSciences Holdings business model

Maravai LifeSciences Holdings is a publicly traded company that was founded in 2014 and is headquartered in San Diego, California. The company operates in the biotechnology industry and specializes in the development and marketing of solutions for the life sciences. Maravai LifeSciences' business model is based on a wide portfolio of products and services, which are divided into various divisions: Nucleic Acid Production & Services, Bio-manufacturing, Bioprocessing, and Nucleic Acid Therapeutics. The Nucleic Acid Production & Services division of Maravai LifeSciences produces synthetic DNA and RNA oligonucleotides that are widely used in biomedical research. These products are utilized by numerous customers worldwide, including researchers, pharmaceutical companies, and diagnostic laboratories. The company also offers a variety of services related to nucleic acid synthesis and oligonucleotide manufacturing. In the Bio-manufacturing division, Maravai LifeSciences provides specifically designed antibodies and proteins that are used in biomedical research and diagnostics. The company also produces specialized reagents and accessories for the scientific community. The Bioprocessing division of Maravai LifeSciences offers solutions for the production of biopharmaceuticals. Here, the company develops technical expertise and manufacturing systems specialized in cellular processes. The goal is to support customers in biopharmaceutical production with more efficient and cost-effective drug manufacturing solutions. The Nucleic Acid Therapeutics division of Maravai LifeSciences develops therapeutic solutions based on DNA and RNA technology. The products are used in cancer research and treatment, as well as gene therapy. The company is dedicated to researching and developing new technologies and products to maintain a leading position in this field. Maravai LifeSciences has earned a reputation in the industry by offering innovative solutions, products, and services. The company works closely with its customers to understand their specific needs and provide tailored solutions. There is a strong commitment to research and development of new technologies and products that will meet the demand arising from the rapid development of the biotechnology industry. Overall, Maravai LifeSciences is a leading company in the development and marketing of solutions for the life sciences. With its wide portfolio of products and services and a strong commitment to research and development, the company is well-equipped to further expand its position in the industry and support its customers worldwide. Maravai LifeSciences Holdings is one of the most popular companies on Eulerpool.com.

Maravai LifeSciences Holdings SWOT Analysis

Strengths

Maravai LifeSciences Holdings Inc possesses several strengths that contribute to its competitive advantage:

  • Strong market presence and brand reputation
  • Wide range of high-quality products and services
  • Innovative research and development capabilities
  • Efficient supply chain management
  • Experienced and skilled workforce
  • Solid financial position

Maravai LifeSciences Holdings Inc faces certain weaknesses that could hinder its growth and performance:

  • Dependence on a limited number of key clients
  • Reliance on specific product lines for revenue generation
  • Limited geographic diversification
  • Potential vulnerability to regulatory changes
  • High research and development costs

Maravai LifeSciences Holdings Inc can capitalize on the following opportunities in the market:

  • Increasing demand for biopharmaceutical products
  • Growing focus on precision medicine and personalized therapies
  • Expansion into emerging markets
  • Strategic partnerships and acquisitions
  • Advancements in genomic sequencing and diagnostics

Maravai LifeSciences Holdings Inc faces certain threats that could potentially impact its business negatively:

  • Intense competition from established and emerging players
  • Regulatory complexities and compliance requirements
  • Uncertainty in government funding for research and development
  • Rapid technological advancements requiring continuous innovation
  • Potential supply chain disruptions

Weaknesses

Maravai LifeSciences Holdings Inc faces certain weaknesses that could hinder its growth and performance:

  • Dependence on a limited number of key clients
  • Reliance on specific product lines for revenue generation
  • Limited geographic diversification
  • Potential vulnerability to regulatory changes
  • High research and development costs

Maravai LifeSciences Holdings Inc can capitalize on the following opportunities in the market:

  • Increasing demand for biopharmaceutical products
  • Growing focus on precision medicine and personalized therapies
  • Expansion into emerging markets
  • Strategic partnerships and acquisitions
  • Advancements in genomic sequencing and diagnostics

Maravai LifeSciences Holdings Inc faces certain threats that could potentially impact its business negatively:

  • Intense competition from established and emerging players
  • Regulatory complexities and compliance requirements
  • Uncertainty in government funding for research and development
  • Rapid technological advancements requiring continuous innovation
  • Potential supply chain disruptions

Opportunities

Maravai LifeSciences Holdings Inc can capitalize on the following opportunities in the market:

  • Increasing demand for biopharmaceutical products
  • Growing focus on precision medicine and personalized therapies
  • Expansion into emerging markets
  • Strategic partnerships and acquisitions
  • Advancements in genomic sequencing and diagnostics

Maravai LifeSciences Holdings Inc faces certain threats that could potentially impact its business negatively:

  • Intense competition from established and emerging players
  • Regulatory complexities and compliance requirements
  • Uncertainty in government funding for research and development
  • Rapid technological advancements requiring continuous innovation
  • Potential supply chain disruptions

Threats

Maravai LifeSciences Holdings Inc faces certain threats that could potentially impact its business negatively:

  • Intense competition from established and emerging players
  • Regulatory complexities and compliance requirements
  • Uncertainty in government funding for research and development
  • Rapid technological advancements requiring continuous innovation
  • Potential supply chain disruptions

Maravai LifeSciences Holdings Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Maravai LifeSciences Holdings historical P/E ratio, EBIT, and P/S ratio.

Maravai LifeSciences Holdings shares outstanding

The number of shares was Maravai LifeSciences Holdings in 2023 — This indicates how many shares 131.919 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Maravai LifeSciences Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Maravai LifeSciences Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Maravai LifeSciences Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Maravai LifeSciences Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Maravai LifeSciences Holdings.

Maravai LifeSciences Holdings latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240 0  (-100 %)2024 Q2
3/31/2024-0.03 -0.02  (23.08 %)2024 Q1
12/31/2023-0.01 0.01  (182.64 %)2023 Q4
9/30/20230.01 -0.01  (-253.85 %)2023 Q3
6/30/20230.01 0  (-100 %)2023 Q2
3/31/20230.04 0.03  (-18.92 %)2023 Q1
12/31/20220.35 0.35  (0.37 %)2022 Q4
9/30/20220.34 0.37  (9.99 %)2022 Q3
6/30/20220.46 0.54  (16.5 %)2022 Q2
3/31/20220.45 0.54  (20.62 %)2022 Q1
1
2

Eulerpool ESG Scorecard© for the Maravai LifeSciences Holdings stock

Eulerpool World ESG Rating (EESG©)

69/ 100

🌱 Environment

86

👫 Social

99

🏛️ Governance

22

Environment

Scope 1 - Direct Emissions
377
Scope 2 - Indirect emissions from purchased energy
1,292
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
1,669
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees46
Percentage of women in management—
Percentage of Asian employees23
Share of Asian management—
Percentage of Hispanic/Latino employees20
Hispano/Latino Management share—
Percentage of Black employees4
Black Management Share—
Percentage of white employees45
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Maravai LifeSciences Holdings list of shareholders

%
Name
Stocks
Change
Date
8.59540 % GTCR Golder Rauner, LLC21,681,033012/31/2023
4.59998 % 12 West Capital Management, L.P.11,602,9885,139,87712/31/2023
3.95675 % The Vanguard Group, Inc.9,980,515-213,38812/31/2023
2.38447 % MFS Investment Management6,014,575-43,67212/31/2023
2.29418 % Millennium Management LLC5,786,849-1,189,07812/31/2023
2.14184 % BlackRock Institutional Trust Company, N.A.5,402,584362,29312/31/2023
2.04931 % Mackenzie Financial Corporation5,169,176238,33512/31/2023
1.99835 % Braidwell LP5,040,6351,065,77812/31/2023
1.38920 % AQR Capital Management, LLC3,504,1111,755,10812/31/2023
1.26724 % Alyeska Investment Group, L.P.3,196,489810,74212/31/2023
1
2
3
4
5
...
10

Maravai LifeSciences Holdings Executives and Management Board

Mr. William Martin48
Maravai LifeSciences Holdings Chief Executive Officer
Compensation 14.52 M
Dr. Peter Leddy59
Maravai LifeSciences Holdings Executive Vice President, Chief Administrative Officer
Compensation 3.92 M
Mr. Carl Hull65
Maravai LifeSciences Holdings Executive Chairman of the Board (since 2020)
Compensation 1.45 M
Mr. Kevin Herde51
Maravai LifeSciences Holdings Chief Financial Officer
Compensation 778,276
Ms. Christine Dolan55
Maravai LifeSciences Holdings Chief Operating Officer - Biologics Safety Testing
Compensation 746,817
1
2
3
4

Maravai LifeSciences Holdings Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Daiichi Sankyo Stock
Daiichi Sankyo
SupplierCustomer0,510,46-0,74-0,02-0,42-
CureVac Stock
CureVac
SupplierCustomer0,380,470,320,570,80-
Shanghai Fosun Pharm H Stock
Shanghai Fosun Pharm H
SupplierCustomer0,380,35-0,150,200,70-
BioNTech ADR Stock
BioNTech ADR
SupplierCustomer0,270,690,250,580,82-
Perella Weinberg A Stock
Perella Weinberg A
SupplierCustomer0,08-0,080,790,320,60-
Pfizer Stock
Pfizer
SupplierCustomer-0,11-0,34-0,38-0,35-0,48-
1

Most common questions regarding Maravai LifeSciences Holdings

What values and corporate philosophy does Maravai LifeSciences Holdings represent?

Maravai LifeSciences Holdings Inc represents a strong commitment to innovation, excellence, and customer satisfaction. The company's corporate philosophy revolves around advancing global health solutions through cutting-edge technologies and scientific expertise. Maravai LifeSciences Holdings Inc values collaboration, integrity, and accountability, driving their mission to provide transformative products and services to the life sciences industry. With a focus on developing and delivering high-quality reagents, analytical instruments, and customized solutions, Maravai LifeSciences Holdings Inc strives to empower researchers, pharmaceutical companies, and diagnostic laboratories in their pursuit of breakthrough discoveries and medical advancements.

In which countries and regions is Maravai LifeSciences Holdings primarily present?

Maravai LifeSciences Holdings Inc is primarily present in the United States.

What significant milestones has the company Maravai LifeSciences Holdings achieved?

Maravai LifeSciences Holdings Inc has achieved several significant milestones. Firstly, the company successfully completed its initial public offering (IPO) on July 1, 2020, becoming a publicly traded company on the NASDAQ stock exchange under the ticker symbol MRVI. Additionally, Maravai has made notable acquisitions, such as the acquisition of MockV Solutions in June 2020, expanding its capabilities in viral vector manufacturing for gene and cell therapies. Moreover, Maravai has reported strong financial growth, with its revenue increasing 46% year-over-year in the second quarter of 2021. The company's dedication to innovation and strategic collaborations has positioned Maravai LifeSciences as a prominent player in the biotech industry.

What is the history and background of the company Maravai LifeSciences Holdings?

Maravai LifeSciences Holdings Inc is a leading life sciences company specializing in providing critical products to enable the development of drug therapies, diagnostics, and vaccines. Founded in 2014, Maravai has rapidly established itself as a key player in the biopharmaceutical industry. The company focuses on four main business units, including nucleic acid production, biologics safety testing, protein detection, and in-vitro diagnostics. Maravai's history is characterized by continuous innovation, strategic partnerships, and a dedication to advancing global health through cutting-edge solutions. With its exceptional track record and unwavering commitment, Maravai LifeSciences Holdings Inc is poised to create a lasting impact in the life sciences field.

Who are the main competitors of Maravai LifeSciences Holdings in the market?

The main competitors of Maravai LifeSciences Holdings Inc in the market include companies such as Thermo Fisher Scientific, Agilent Technologies, and Illumina Inc. These companies also operate in the life sciences industry, offering a wide range of products and services, including laboratory instruments, reagents, and genomic solutions. However, Maravai LifeSciences Holdings Inc distinguishes itself through its expertise in the development of reagents and advanced technologies for the life sciences research community. With its innovative product portfolio and strong market presence, Maravai continues to compete effectively against its rivals in the industry.

In which industries is Maravai LifeSciences Holdings primarily active?

Maravai LifeSciences Holdings Inc is primarily active in the biotechnology and life sciences industries.

What is the business model of Maravai LifeSciences Holdings?

Maravai LifeSciences Holdings Inc operates as a life sciences company that provides products and services to enable the development of drug therapies, diagnostics, and vaccines. The company's business model focuses on offering a comprehensive range of integrated solutions, including specialized reagents, consumables, software, and assay platforms. By leveraging its expertise in nucleic acid synthesis, bioprocess impurity testing, and protein labeling, Maravai supports the research and development efforts of pharmaceutical and biotechnology companies globally. As a trusted partner for life science applications, Maravai aims to accelerate scientific discoveries and improve patient outcomes through its innovative and customizable products and services.

What is the P/E ratio of Maravai LifeSciences Holdings 2024?

The Maravai LifeSciences Holdings P/E ratio is -139.81.

What is the P/S ratio of Maravai LifeSciences Holdings 2024?

The Maravai LifeSciences Holdings P/S ratio is 4.13.

What is the AlleAktien quality score of Maravai LifeSciences Holdings?

The AlleAktien quality score for Maravai LifeSciences Holdings is 1/10.

What is the revenue of Maravai LifeSciences Holdings 2024?

The expected Maravai LifeSciences Holdings revenue is 281.11 M USD.

How high is the profit of Maravai LifeSciences Holdings 2024?

The expected Maravai LifeSciences Holdings profit is -8.31 M USD.

What is the business model of Maravai LifeSciences Holdings

Maravai LifeSciences Holdings Inc. is a specialized biotechnology company focused on the development and manufacturing of products for large-scale biopharmaceutical production, in-vitro diagnostics, and research. The company focuses on developing innovative technologies and products that contribute to improving the health and well-being of humans and animals. It consists of three main areas: TriLink BioTechnologies, Vector Laboratories, and Cygnus Technologies, each specializing in developing products for the biopharmaceutical market. TriLink BioTechnologies manufactures reagents for nucleic acid synthesis and modification, as well as oligonucleotide-based genetics for body fluid analysis. Vector Laboratories is a leading provider of reagents for immunohistochemistry (IHC) and immunocytochemistry (ICC), including antibodies, kits, buffers, and reactivity cards. Cygnus Technologies is a leading manufacturer of products for the analysis of biopharmaceutical proteins, including ELISA kits, antibodies, protein markers, and reagents for protein purification. Maravai LifeSciences Holdings Inc. aims to develop innovative technologies and products that contribute to process improvement and cost savings. The company's products are designed to assist customers in the biopharmaceutical industry in focusing on drug development and therapy. Maravai also continuously invests in research and development to develop new technologies and products, always striving to offer customers the best and most innovative products. Overall, Maravai LifeSciences Holdings Inc. delivers innovative products that help customers in the biopharmaceutical industry optimize processes, maximize efficiency, and reduce costs. The company is committed to constantly evolving its products to provide customers with better solutions. Thanks to its ability to develop and deliver innovative products to its customers, Maravai LifeSciences Holdings Inc. remains a key player in the biopharmaceutical industry.

What is the Maravai LifeSciences Holdings dividend?

Maravai LifeSciences Holdings pays a dividend of 0 USD distributed over payouts per year.

How often does Maravai LifeSciences Holdings pay dividends?

The dividend cannot currently be calculated for Maravai LifeSciences Holdings or the company does not pay out a dividend.

What is the Maravai LifeSciences Holdings ISIN?

The ISIN of Maravai LifeSciences Holdings is US56600D1072.

What is the Maravai LifeSciences Holdings WKN?

The WKN of Maravai LifeSciences Holdings is A2QHK8.

What is the Maravai LifeSciences Holdings ticker?

The ticker of Maravai LifeSciences Holdings is MRVI.

How much dividend does Maravai LifeSciences Holdings pay?

Over the past 12 months, Maravai LifeSciences Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Maravai LifeSciences Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Maravai LifeSciences Holdings?

The current dividend yield of Maravai LifeSciences Holdings is .

When does Maravai LifeSciences Holdings pay dividends?

Maravai LifeSciences Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Maravai LifeSciences Holdings?

Maravai LifeSciences Holdings paid dividends every year for the past 0 years.

What is the dividend of Maravai LifeSciences Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Maravai LifeSciences Holdings located?

Maravai LifeSciences Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Maravai LifeSciences Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Maravai LifeSciences Holdings from 9/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.

When did Maravai LifeSciences Holdings pay the last dividend?

The last dividend was paid out on 9/12/2024.

What was the dividend of Maravai LifeSciences Holdings in the year 2023?

In the year 2023, Maravai LifeSciences Holdings distributed 0 USD as dividends.

In which currency does Maravai LifeSciences Holdings pay out the dividend?

The dividends of Maravai LifeSciences Holdings are distributed in USD.

All fundamentals about Maravai LifeSciences Holdings

Our stock analysis for Maravai LifeSciences Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Maravai LifeSciences Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.